We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
Read MoreHide Full Article
AstraZeneca, plc (AZN - Free Report) announced that the European Commission (“EC”) has granted approval to its asthma disease candidate, benralizumab. It is approved as an add-on maintenance treatment for severe eosinophilic asthma in adult patients. It will be marketed by the trade name of Fasenra.
With this approval, Fasenra is the first respiratory biologic drug to have an 8-week maintenance dosing schedule. The drug will be available in a fixed-dose subcutaneous injection via a prefilled syringe.
We remind investors that Fasenra received approval in the same indication in the United States in November last year. It is also under review in Japan
AstraZeneca’s shares have gained 25.1% in the past year, comparing favorably with the industry’s growth of 18.4% in that period.
The EC approved Fasenra based on data from the WINDWARD program, which included three phase III studies – SIROCCO, CALIMA and ZONDA.
Data from SIROCCO and CALIMA showed that Fasenra achieved significant reductions in exacerbations and improvements in lung function. Meanwhile, data from ZONDA study showed that Fasenra alone or in combination with standard of care (glucocorticoid) led to statistically-significant and clinically relevant reduction in daily maintenance oral corticosteroid (“OCS”) compared with placebo.
Severe asthma patients whose disease is driven by inflammation of eosinophils, a type of white blood cell, have until now had only limited treatment options, mostly oral steroids. Fasenra, which distinctively targets and rapidly depletes eosinophils, has shown potential to reduce oral steroid use in such patients.
GlaxoSmithKline’s (GSK - Free Report) Nucala (subcutaneous administration) and Teva Pharmaceutical Industries' (TEVA - Free Report) Cinqair (intravenous infusion) are presently marketed for the same indication but administered once every four weeks.
Asthma is a chronic inflammatory disease of breathlessness and has a significant unmet medical need. This affects 315 million individuals worldwide and up to 10% of patients who have severe asthma, which can become uncontrolled despite receiving high doses of standard of care medicines and require the use of chronic OCS.
Benralizumab is also being evaluated for the treatment of chronic obstructive pulmonary disease ("COPD") in late-stage studies. Other severe asthma candidates in AstraZeneca’s portfolio are tralokinumab and tezepelumab — in partnership with Amgen, Inc. (AMGN - Free Report) .
AstraZeneca’s respiratory portfolio accounted for 23% of total product sales in the first nine months of 2017. The segment saw a decline in sales in the period due to competition and other market conditions. However, addition of another drug in the portfolio will certainly boost performance.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
AstraZeneca, plc (AZN - Free Report) announced that the European Commission (“EC”) has granted approval to its asthma disease candidate, benralizumab. It is approved as an add-on maintenance treatment for severe eosinophilic asthma in adult patients. It will be marketed by the trade name of Fasenra.
With this approval, Fasenra is the first respiratory biologic drug to have an 8-week maintenance dosing schedule. The drug will be available in a fixed-dose subcutaneous injection via a prefilled syringe.
We remind investors that Fasenra received approval in the same indication in the United States in November last year. It is also under review in Japan
AstraZeneca’s shares have gained 25.1% in the past year, comparing favorably with the industry’s growth of 18.4% in that period.
The EC approved Fasenra based on data from the WINDWARD program, which included three phase III studies – SIROCCO, CALIMA and ZONDA.
Data from SIROCCO and CALIMA showed that Fasenra achieved significant reductions in exacerbations and improvements in lung function. Meanwhile, data from ZONDA study showed that Fasenra alone or in combination with standard of care (glucocorticoid) led to statistically-significant and clinically relevant reduction in daily maintenance oral corticosteroid (“OCS”) compared with placebo.
Severe asthma patients whose disease is driven by inflammation of eosinophils, a type of white blood cell, have until now had only limited treatment options, mostly oral steroids. Fasenra, which distinctively targets and rapidly depletes eosinophils, has shown potential to reduce oral steroid use in such patients.
GlaxoSmithKline’s (GSK - Free Report) Nucala (subcutaneous administration) and Teva Pharmaceutical Industries' (TEVA - Free Report) Cinqair (intravenous infusion) are presently marketed for the same indication but administered once every four weeks.
Asthma is a chronic inflammatory disease of breathlessness and has a significant unmet medical need. This affects 315 million individuals worldwide and up to 10% of patients who have severe asthma, which can become uncontrolled despite receiving high doses of standard of care medicines and require the use of chronic OCS.
Benralizumab is also being evaluated for the treatment of chronic obstructive pulmonary disease ("COPD") in late-stage studies. Other severe asthma candidates in AstraZeneca’s portfolio are tralokinumab and tezepelumab — in partnership with Amgen, Inc. (AMGN - Free Report) .
AstraZeneca’s respiratory portfolio accounted for 23% of total product sales in the first nine months of 2017. The segment saw a decline in sales in the period due to competition and other market conditions. However, addition of another drug in the portfolio will certainly boost performance.
Astrazeneca PLC Price
Astrazeneca PLC Price | Astrazeneca PLC Quote
AstraZeneca carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>